# BillionToOne Hits $123M Quarterly Revenue, Scaling Prenatal and Oncology Testing in Menlo Park **Author:** Zero G Talent **Published:** 2026-11-13 **Category:** engineering **Tags:** yc-hiring, molecular diagnostics, genomics, bioinformatics, software engineering, ai engineering [Read on Zero G Talent](https://zerogtalent.com/blog/billiontoone-hits-123m-quarterly-revenue-scaling-prenatal-and-oncology-testing-in-menlo-park) --- Molecular diagnostics company [BillionToOne](https://zerogtalent.com/frontier-companies/billiontoone) reached $123 million in revenue for the third quarter of 2026, marking a 47% year-over-year increase and bringing its annualized run rate to $492 million. According to earnings details reported by [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/billiontoone-inc-blln-q3-2026-071404551.html), the performance marked the company's fifth consecutive quarter of positive GAAP operating income, driven by a 42% revenue increase in prenatal testing to $105.9 million and a 96% jump in oncology revenue to $17.1 million. Following its initial public offering, the Menlo Park, California-based company processed approximately 206,000 tests during the quarter. BillionToOne is expanding beyond its initial focus on noninvasive prenatal screening into liquid biopsy assays for cancer, with plans to launch its tissue-free Northstar Clear minimal residual disease (MRD) test on December 15, 2026. ## Single-Molecule Resolution in Cell-Free DNA Founded in 2016 out of Y Combinator's S17 batch by [Oguzhan Atay](https://zerogtalent.com/people/oguzhan-atay), [David Tsao](https://zerogtalent.com/people/david-tsao), and [Sukrit Silas](https://zerogtalent.com/people/sukrit-silas), BillionToOne built its platform to address a core limitation of standard genetic testing. Detecting fetal genetic conditions or early cancer mutations from circulating cell-free DNA (cfDNA) in blood requires isolating signals that may make up less than 0.01% of total DNA. Conventional next-generation sequencing uses polymerase chain reaction (PCR) to amplify sparse DNA fragments, but the amplification process adds noise that obscures faint single-gene alterations. BillionToOne developed Quantitative Counting Templates (QCT), synthetic DNA molecules added to samples before amplification. As explained in a company technical overview video on [YouTube](https://www.youtube.com/watch?v=Lwkjh6ki6HE), these synthetic markers mirror patient DNA sequences, allowing machine learning algorithms to identify and remove amplification errors to achieve single-molecule counting resolution. CEO [Oguzhan Atay](https://zerogtalent.com/people/oguzhan-atay), who completed his Ph.D. in systems biology at Stanford University, and CTO [David Tsao](https://zerogtalent.com/people/david-tsao), who earned a Ph.D. in bioengineering from Rice University, structured the R&D organization around small, interdisciplinary teams. In an interview with [Y Combinator](https://www.youtube.com/watch?v=kkv5rZhrLkc), Atay noted that individual principal investigators lead teams of two to three research associates that own product development end-to-end, combining experimental biology with computational analysis. ## Expanding Prenatal and Liquid Biopsy Assays BillionToOne's flagship prenatal test, the UNITY Screen, evaluates fetal risk for single-gene recessive conditions—including sickle cell disease, cystic fibrosis, and spinal muscular atrophy—directly from a single maternal blood draw without requiring a paternal sample. In March 2025, [PR Newswire](https://www.prnewswire.com/news-releases/billiontoone-celebrates-major-milestone-1-million-unity-tests-302404557.html) reported that the company had conducted more than one million UNITY tests. The company broadened its prenatal capabilities in May 2026 with the launch of Unity Confirm. Reported by [Healio](https://www.healio.com/news/womens-health-ob-gyn/20260501/billiontoone-launches-unity-confirm-a-noninvasive-blood-test-for-highrisk-pregnancies), the test selectively captures intact circulating fetal cells from blood samples to perform whole-genome sequencing at near-complete fetal fraction, offering a noninvasive confirmatory alternative for high-risk screening results. In oncology, BillionToOne has launched multiple liquid biopsy applications under its Northstar umbrella: - **Northstar Select & Response**: Comprehensive genomic profiling across 102 genes and a tissue-free response monitoring test that quantifies changes in tumor DNA over serial blood draws. - **Northstar PGx & Select CH**: Launched in February 2026 to assess pharmacogenomic variants in DPYD and UGT1A1 for chemotherapy safety, while filtering out false positives caused by clonal hematopoiesis. - **Northstar Origin**: Introduced in September 2026 as a liquid biopsy add-on that combines methylation profiling and somatic variants to predict tissue of origin in cancers of unknown primary. To streamline clinical adoption across health systems, BillionToOne integrated its prenatal and oncology portfolios with Epic's Aura diagnostics suite in January 2026, enabling ordering and discrete result reporting directly within electronic health records. ## Engineering and Operational Hiring BillionToOne employs roughly 300 staff members across laboratory operations, bioinformatics, software engineering, and commercial functions. Software engineering work spans a core technical stack that includes Python, Django, PostgreSQL, AWS, Heroku, and specialized genomics tools such as the Genome Analysis Toolkit (GATK), samtools, and bedtools. To keep pace with physical sample processing, the company redesigned its laboratory intake process using computer vision and AI automation to handle accessioning in under 60 seconds per sample. The company is actively recruiting technical and strategic talent across several hybrid roles in Menlo Park, CA: - For executive operations, the [Director, Office of the CEO, Founder in Residence Program](https://zerogtalent.com/frontier-jobs/billiontoone/director-office-of-the-ceo-founder-in-residence-program-97725) ($204,000–$225,000 USD/year) works on-site alongside leadership on high-priority strategic projects and business incubation before transitioning into a permanent senior operating role. - Operational automation is led by roles like the [Senior AI Engineer I](https://zerogtalent.com/frontier-jobs/billiontoone/senior-ai-engineer-i-93975) ($174,000–$201,000 USD/year), which designs LLM-powered applications and workflows to automate processes for commercial, billing, and customer experience teams. - Platform infrastructure and patient applications are built by roles such as the [Senior Software Engineer, Prenatal](https://zerogtalent.com/frontier-jobs/billiontoone/senior-software-engineer-prenatal-90769) ($190,000–$211,000 USD/year) and the [Senior Software Engineer, Digital Experiences (Prenatal)](https://zerogtalent.com/frontier-jobs/billiontoone/senior-software-engineer-digital-experiences-prenatal-90768) ($190,000–$211,000 USD/year), which construct backend microservices, APIs, and clinician-facing software for electronic medical record integration. ## Open Roles at BillionToOne | Role | Location | Work Mode | Salary | | --- | --- | --- | --- | | [Director, Office of the CEO, Founder in Residence Program](https://zerogtalent.com/frontier-jobs/billiontoone/director-office-of-the-ceo-founder-in-residence-program-97725) | Menlo Park, CA, US | Onsite | $204,000–$225,000 USD/year | | [Senior AI Engineer I](https://zerogtalent.com/frontier-jobs/billiontoone/senior-ai-engineer-i-93975) | Menlo Park, CA | Onsite | $174,000–$201,000 USD/year | | [Senior Software Engineer, Prenatal](https://zerogtalent.com/frontier-jobs/billiontoone/senior-software-engineer-prenatal-90769) | Menlo Park, CA, US | Onsite | $190,000–$211,000 USD/year | | [Senior Software Engineer, Digital Experiences (Prenatal)](https://zerogtalent.com/frontier-jobs/billiontoone/senior-software-engineer-digital-experiences-prenatal-90768) | Menlo Park, CA, US | Onsite | $190,000–$211,000 USD/year | [See all open roles at BillionToOne](https://zerogtalent.com/frontier-companies/billiontoone) --- *Source: [Zero G Talent](https://zerogtalent.com), the job board for space, defense, AI, robotics and frontier-tech companies.*